RLAY

5.95

1.71% 0.10

Dopo l'orario di chiusura: 6.07 0.12 +2.02%

Relay Therapeutics Inc (RLAY)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché RLAY Giù? Forum Previsione

Precedente Chiudi:

$5.85

Aprire:

$5.78

Volume 24 ore:

1.04M

Relative Volume:

0.55

Capitalizzazione di mercato:

$966.65M

Reddito:

$25.55M

Utile/perdita netta:

$-341.97M

Rapporto P/E:

-2.2119

EPS:

-2.69

Flusso di cassa netto:

$-304.44M

1 W Prestazione:

+0.85%

1M Prestazione:

-8.88%

6M Prestazione:

-15.48%

1 anno Prestazione:

-20.88%

Intervallo 1D:

$5.66

$6.00

Intervallo di 1 settimana:

$5.60

$6.09

Portata 52W:

$5.60

$12.14

Relay Therapeutics Inc Stock (RLAY) Company Profile

Nome

Relay Therapeutics Inc

Settore

Healthcare (1182)

Industria

Biotechnology (671)

Telefono

617-370-8837

Indirizzo

399 BINNEY STREET, CAMBRIDGE

Dipendente

304

Cinguettio

Prossima data di guadagno

2024-11-06

Ultimi documenti SEC

RLAY's Discussions on Twitter

Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-04-20	Aggiornamento	Jefferies	Underperform → Hold
2023-04-19	Aggiornamento	Raymond James	Outperform → Strong Buy
2023-04-13	Iniziato	Raymond James	Outperform
2023-02-03	Iniziato	Oppenheimer	Outperform
2022-09-30	Iniziato	Barclays	Equal Weight
2022-09-02	Iniziato	Stifel	Buy
2022-06-06	Iniziato	Jefferies	Underperform
2022-02-01	Iniziato	Berenberg	Buy
2021-07-21	Iniziato	BofA Securities	Buy
2020-12-15	Reiterato	H.C. Wainwright	Buy
2020-12-08	Iniziato	JMP Securities	Mkt Outperform
2020-11-05	Iniziato	H.C. Wainwright	Buy
2020-08-10	Iniziato	Cowen	Outperform
2020-08-10	Iniziato	Goldman	Buy
2020-08-10	Iniziato	Guggenheim	Buy
2020-08-10	Iniziato	JP Morgan	Neutral

Mostra tutto

Relay Therapeutics Inc Borsa (RLAY) Ultime notizie

Nov 04, 2024

Relay Therapeutics stock hits 52-week low at $5.7 amid market shifts - Investing.com India

Oct 31, 2024

Oct 30, 2024

Relay Therapeutics stock hits 52-week low at $5.7 amid market shifts By Investing.com - Investing.com South Africa

Oct 30, 2024

Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024 - The Manila Times

Oct 30, 2024

Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, - EIN News

Oct 30, 2024

Oct 29, 2024

Intrahepatic Cholangiocarcinoma Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Key Companies involved by DelveInsight | Xencor, Relay Therapeutics, Kinnate Biopharma, Forma Therapy - Barchart

Oct 29, 2024

Oct 28, 2024

Institutional owners may consider drastic measures as Relay Therapeutics, Inc.'s (NASDAQ:RLAY) recent US$67m drop adds to long-term losses - Yahoo Finance

Oct 28, 2024

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Oct 28, 2024

Oct 25, 2024

Several Relay Therapeutics Insiders Sell Shares Sending Potential Negative Signal - Simply Wall St

Oct 25, 2024

Relay Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal phase - Investing.com Canada

Oct 25, 2024

Oct 24, 2024

Relay Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal phase By Investing.com - Investing.com South Africa

Oct 24, 2024

Oct 16, 2024

Financial Snapshot: Analyzing Relay Therapeutics Inc (RLAY)’s Key Ratio Metrics - The Dwinnex

Oct 16, 2024

Oct 15, 2024

Relay Therapeutics, Inc. (NASDAQ:RLAY) Short Interest Update - MarketBeat

Oct 15, 2024

Oct 14, 2024

How did Relay Therapeutics Inc (RLAY) fare last session? - US Post News

Oct 14, 2024

Relay Therapeutics (NASDAQ:RLAY) Receives Buy Rating from HC Wainwright - MarketBeat

Oct 14, 2024

Relay Therapeutics stock holds price target on FDA approval By Investing.com - Investing.com UK

Oct 14, 2024